- Home
- MARPS vs NLSP Comparison
MARPS vs NLSP Comparison
Compare MARPS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- NLSP
- Stock Information
- Founded
- MARPS 1956
- NLSP 2015
- Country
- MARPS United States
- NLSP Switzerland
- Employees
- MARPS N/A
- NLSP N/A
- Industry
- MARPS Oil & Gas Production
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- MARPS Energy
- NLSP Health Care
- Exchange
- MARPS Nasdaq
- NLSP Nasdaq
- Market Cap
- MARPS 7.5M
- NLSP 12.4M
- IPO Year
- MARPS N/A
- NLSP 2021
- Fundamental
- Price
- MARPS $4.55
- NLSP $2.10
- Analyst Decision
- MARPS
- NLSP
- Analyst Count
- MARPS 0
- NLSP 0
- Target Price
- MARPS N/A
- NLSP N/A
- AVG Volume (30 Days)
- MARPS 246.8K
- NLSP 275.3K
- Earning Date
- MARPS 01-01-0001
- NLSP 07-22-2025
- Dividend Yield
- MARPS 8.00%
- NLSP N/A
- EPS Growth
- MARPS N/A
- NLSP N/A
- EPS
- MARPS 0.36
- NLSP N/A
- Revenue
- MARPS $1,036,019.00
- NLSP N/A
- Revenue This Year
- MARPS N/A
- NLSP N/A
- Revenue Next Year
- MARPS N/A
- NLSP N/A
- P/E Ratio
- MARPS $12.48
- NLSP N/A
- Revenue Growth
- MARPS N/A
- NLSP N/A
- 52 Week Low
- MARPS $3.34
- NLSP $1.30
- 52 Week High
- MARPS $7.90
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- MARPS 49.70
- NLSP 46.61
- Support Level
- MARPS $4.43
- NLSP $2.20
- Resistance Level
- MARPS $4.88
- NLSP $3.08
- Average True Range (ATR)
- MARPS 0.44
- NLSP 0.25
- MACD
- MARPS -0.07
- NLSP -0.06
- Stochastic Oscillator
- MARPS 15.49
- NLSP 8.40
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.